FDA approves Gilead's Remdesivir as Covid-19 treatment
The FDA has approved Gilead's Remdesivir as a Covid-19 treatment. Previously, the drug was approved only for emergency authorization. Gilead stock was up 4 percent after the news. Meg Tirrell joins 'Closing Bell' to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео FDA approves Gilead's Remdesivir as Covid-19 treatment канала CNBC Television
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
Видео FDA approves Gilead's Remdesivir as Covid-19 treatment канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
FDA approves Gilead's Remdesivir as a coronavirus treatmentCoronavirus: Gilead's Remdesivir receives FDA approval to treat COVID-19 patientsWhy this analyst has an outperform rating on Tesla: 'It's about the process tech'Sacha Baron Cohen responds to Rudy Giuliani’s claims about ‘Borat’ scene l GMAWATCH LIVE: World Health Organization holds briefing on the coronavirus outbreak — 10/23/2020Kornacki Breaks Down Where Things Stand In Battleground States Heading Into Final Debate | MSNBCThe 8 Flights That Show How COVID-19 Reinvented AviationCoronavirus Update 113: Remdesivir May Not Work for COVID 19Former FDA chief Dr. Scott Gottlieb on remdesivir Covid-19 treatment study: 'Results were strong'Paul Tudor Jones on bitcoin: It's like investing early in a tech companyThere's A Crisis That Is Quietly Creating New Economic Superpowers...COVID19 - What's Going on in CHINA with Coronavirus?! | JaYoe Conversation76K US cases mark highest 1-day total l GMAInside Lucid Motors' Plan To Take On TeslaJim Cramer reveals top stocks in 7 under-the-radar bull marketsFDA approves remdesivir as COVID-19 treatmentIntel shares sell off after company reports 7% decline in data center revenueCovid-19 treatment will not be widely available and will have to be rationed: Former FDA chiefTrump Says Virus Spikes Have Gone Away When They Haven't | Morning Joe | MSNBCNYT’s Haberman: “Joe Biden Might End Up Regretting” His Pledge To End The Oil Industry